Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Susoctocog alfa for major surgery in acquired Hemophilia A

Inga Schimansky, Christiane Dobbelstein, Andreas Tiede Nov 03, 2025 pp. 4866-4866 10.1182/blood-2025-4866

Abstract Acquired hemophilia A (AHA) is a rare but serious bleeding disorder caused by autoantibodies against coagulation factor VIII (FVIII...

Association of opioid use disorder and thrombotic events in hospitalized patients: A national inpatient database study

Kristy Bono, Safia Ansari, Anand Shah et al. Nov 03, 2025 pp. 6247-6247 10.1182/blood-2025-6247

Abstract Introduction Thrombotic events, such as deep vein thrombosis (DVT), pulmonary embolism (PE), and arterial throm...

Enhanced chimerism detection with multiple single Nucleotide Polymorphism Sequencing: Improving risk stratification post-allogeneic hematopoietic stem cell transplantation

Zhe Zou, Yangwei Li, Desheng Gong et al. Nov 03, 2025 pp. 2527-2527 10.1182/blood-2025-2527

Abstract Introduction Chimerism (CHIM) analysis following allogeneic hematopoietic stem cell transplantation (aHSCT) is critical for assessi...

Paused RNA polymerase II enables flexible lineage decisions but also underlies oncogenic vulnerabilities in human hematopoiesis

Derek Janssens, Alexandria Eiken, Emma Baird et al. Nov 03, 2025 pp. 207-207 10.1182/blood-2025-207

Abstract During inflammation, hematopoietic stem cells (HSCs) must integrate environmental stimuli to generate the appropriate myeloid and l...

Lentiviral vectors engineered for direct In Vivo delivery to resting T cells

Gopal Naik Nenavath, Md Sharif Hasan, Nainika Ravichandran et al. Nov 03, 2025 pp. 5902-5902 10.1182/blood-2025-5902

Abstract Direct in vivo T cell engineering offers a new paradigm for CAR T delivery. We have evaluated several approaches to engineer lentiv...

Spontaneous remissions in paroxysmal nocturnal hemoglobinuria: True remission or clonal evolution to malignancy?

Caitlin Roger, Matthew Holt, Louise Arnold et al. Nov 03, 2025 pp. 29-29 10.1182/blood-2025-29

Abstract Background Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal hematopoietic disorder driven by a deficiency of glycosylphos...

Intermediate-dose (0.4 g/kg per Dose) versus standard high-dose (1.0 g/kg per Dose) intravenous immunoglobulin in pediatric primary immune thrombocytopenia: A multicenter randomized non-inferiority trial

Yongzhi Zheng, Haixia Zhou, Biyun Guo et al. Nov 03, 2025 pp. 737-737 10.1182/blood-2025-737

Abstract Background and Objectives Children presenting to emergency departments with newly diagnosed immune thrombocytop...

Real-world use of loncastuximab tesirine in heavily pretreated and high risk relapsed/refractory large B-cell lymphoma patients: German multicenter analysis

Evgenii Shumilov, Débora-Michèle Grote Urtubey, Marcel Teichert et al. Nov 03, 2025 pp. 5473-5473 10.1182/blood-2025-5473

Abstract Patients (pts) with large B-cell lymphoma (LBCL) relapsing or being refractory (r/r) following two prior systemic therapies are par...

Decoding CAR t cell membrane architecture with the proximity network assay

Hanna van Ooijen, Divya Thiagrajan, Filip Karlsson et al. Nov 03, 2025 pp. 5874-5874 10.1182/blood-2025-5874

Abstract Membrane protein organization plays a critical role in shaping CAR T cell function, yet current tools lack the resolution to study...

Risk of death and comorbidities in β-thalassemia carriers identified by consecutive genotyping: A prospective cohort study of 467,242 general population individuals

Lilla Gaál, Marie Warny, Jesper Petersen et al. Nov 03, 2025 pp. 2661-2661 10.1182/blood-2025-2661

Abstract Introduction:Approximately 1.5% of the global population are heterozygous carriers of β-thalassemia. While the condition is typical...

Characterization of the germline and somatic mutation profile of diamond-blackfan anemia

Luiz Catto, Fernanda Gutierrez-Rodrigues, Matthew Gianferante et al. Nov 03, 2025 pp. 4993-4993 10.1182/blood-2025-4993

Abstract Diamond-Blackfan Anemia (DBA) is a ribosomopathy characterized by isolated hypoplastic anemia, phenotypic abnormalities and cancer...

A phase I monotherapy study assessing the safety and efficacy of GR1803, a BCMA×CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma

Min Yang, Yang Liang, Guorong Wang et al. Nov 03, 2025 pp. 5822-5822 10.1182/blood-2025-5822

Abstract Background: Outcomes remain poor for patients with relapsed or refractory Multiple Myeloma (RRMM). GR1803 is a BCMA x CD3 bispecifi...

A real-world multi-institution experience of standard vs alternative dosing of inotuzumab ozogamicin for Relapsed/Refractory pediatric B-cell acute lymphoblastic leukemia

Morgan Drucker, Catherine Aftandilian, Kara Davis et al. Nov 03, 2025 pp. 1570-1570 10.1182/blood-2025-1570

Abstract Background: Inotuzumab ozogamicin (InO) is an active agent in children and adults with relapsed/refractory (R/R) B-cell acute lymph...

Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy for pediatirc relapsed and Refractory Acute lymphoblastic leukemia followed by TCRαβ-depleted haplo-HSCT

Huaying Liu, Jing Wang, Simeng lv et al. Nov 03, 2025 pp. 2529-2529 10.1182/blood-2025-2529

Abstract Background and aim: TCRαβ-depleted HLA-haploidentical stem cell transplantation(TCD Haplo-HSCT) represents a promising curative opt...

Tislelizumab combined with zanubrutinib and high-dose methotrexate in newly diagnosed primary central nervous system DLBCL: A phase 2 study

Xia Zhao, Zhihe Liu, Guoqiang Liu et al. Nov 03, 2025 pp. 1909-1909 10.1182/blood-2025-1909

Abstract Background: Primary central nervous system diffuse large B-cell lymphoma (PCNS-DLBCL) is a rare subtype of non-Hodgkin lymphoma wit...

Real-world patient-based next-generation sequencing assessments identify a high-risk subgroup and associated gene signature in diffuse large B cell lymphoma

Hocheol Jang, Ga-Young Song, Seung Jung Han et al. Nov 03, 2025 pp. 7072-7072 10.1182/blood-2025-7072

Abstract Diffuse large B cell lymphoma (DLBCL) exhibits profound genetic heterogeneity that drives disparate clinical outcomes despite stand...

Relapsed acute lymphoblastic leukemia treated with venetoclax and navitoclax: Results of the raven study in children and young adults with relapsed/ refractory ALL

Seth Karol, Maria Luisa Sulis, Yinmei Zhou et al. Nov 03, 2025 pp. 5126-5126 10.1182/blood-2025-5126

Abstract Acute lymphoblastic leukemia (ALL) is the most common malignancy of childhood. While frontline therapy is highly effective, 10-20%...

More than iron: Embedding gynecologic care in a telemedicine IDA platform

Josette Kamel, Natasha Radojcic, Macheline Dupont et al. Nov 03, 2025 pp. 596-596 10.1182/blood-2025-596

Abstract e-Iron is a telemedicine platform developed at our institution to facilitate the administration of intravenous iron (IVI) to approp...

A novel predictive model for posttransplant lymphoproliferative disorder in the letermovir prophylaxis era

Chen-Cong Wang, Xuying Pei, Hai-Xia Fu et al. Nov 03, 2025 pp. 4269-4269 10.1182/blood-2025-4269

Abstract Introduction Posttransplant lymphoproliferative disorder (PTLD) is a complication following allogeneic hematopoietic stem cell tran...

Adjudicated clinical outcomes of plasma microbial cell-free DNA surveillance in neutropenic patients with Acute Myeloid Leukemia undergoing outpatient chemotherapy

Michael Mansour, Amir Fathi, Andrew Brunner et al. Nov 03, 2025 pp. 5189-5189 10.1182/blood-2025-5189

Abstract Background/Objectives: The main objective of this proof-of-concept study is to assess the clinical impact of microbial cell-free DN...

Prolonged cytopenias after BCMA CAR‑T are associated with impaired endogenous T cell recovery characterized by decreased CD8+ T cell diversity

Abigail Chutnik, Zachary Avigan, Ramy Mahmoud et al. Nov 03, 2025 pp. 2290-2290 10.1182/blood-2025-2290

Abstract Chimeric antigen receptor T cells (CAR-T) targeting B-cell maturation antigen (BCMA) have transformed the treatment landscape for m...

Prenatal transplantation of a clinical cell product engineered to secrete FVIII in a sheep with Hemophilia A corrects the severe bleeding phenotype and prevents hemarthroses

M. Graca Almeida-Porada, Walaa Mohamed, Martin Rodriguez et al. Nov 03, 2025 pp. 1064-1064 10.1182/blood-2025-1064

Abstract Prenatal treatment (PNT) of people with hemophilia A (HA) is a feasible, safe, yet unexplored clinical approach, consisting of an u...

Adapting the American society of hematology crti-la model to build clinical research capacity in Mexico: Results from the ameh-I3 course

Andres Gomez-De Leon, Roberta Demichelis, Christianne Bourlon et al. Nov 03, 2025 pp. 4653-4653 10.1182/blood-2025-4653

Abstract Introduction: Building research capacity is essential for advancing evidence-based clinical practice. However, access to structured...

Beyond complement: Patient and in vitro evidence for alternative mechanisms of Monocyte–Platelet aggregation in PNH

Nora Sophia Rogmann, Frederic Ries, Cornelia Schmidt et al. Nov 03, 2025 pp. 2988-2988 10.1182/blood-2025-2988

Abstract Background: Paroxysmal nocturnal haemoglobinuria (PNH) is a clonal haematopoietic stem cell disorder characterised by the absence o...

Klippel-trenaunay syndrome with multifactorial anemia:successful management with sirolimus

Chen Yang Nov 03, 2025 pp. 6444-6444 10.1182/blood-2025-6444

Abstract Objective:Klippel-Trenaunay Syndrome (KTS), a rare congenital disorder characterized by capillary malformations, venous varicositi...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page